Connect Biopharma Holdings Ltd 8-K

What Happened

• Connect Biopharma Holdings Ltd. announced a securities purchase agreement for a private placement of 6,130,000 ordinary shares at $3.25 per share, expected to raise approximately $20.2 million in gross proceeds. The Company expects the transaction to close on March 31, 2026, subject to customary closing conditions. Leerink Partners LLC and Cantor Fitzgerald & Co. acted as joint placement agents.
• The Company issued press releases (March 30, 2026) reporting topline preliminary results from its Phase 1 IV rademikibart clinical pharmacology study and results from a Phase 3 52-week study in moderate-to-severe atopic dermatitis conducted by partner Simcere in China. A press release announcing the Purchase Agreement was also issued.

Key Details

• Shares and price: 6,130,000 ordinary shares at $3.25 per share; ~ $20.2M gross proceeds (before fees and expenses).
• Closing & registration: Private Placement expected to close March 31, 2026; Company must file a resale registration statement within 45 days after closing and use reasonable best efforts to have it declared effective.
• Use of proceeds & runway: Net proceeds intended for R&D of clinical-stage candidates, other development programs, working capital and general corporate purposes; Company estimates cash, plus net proceeds, will fund operations into the second half of 2027.
• Sale mechanics: Offered to institutional accredited investors in a transaction exempt from SEC registration (Section 4(a)(2)/Rule 506 of Regulation D); purchasers represented no present intent to distribute securities.

Why It Matters

• The private placement provides near-term financing to support Connect Biopharma’s clinical programs and general operations, extending its reported cash runway into H2 2027 per management’s estimate.
• The Company’s simultaneous disclosure of Phase 1 IV rademikibart topline data and Simcere’s Phase 3 AD results are material clinical updates that investors should review for potential impacts on development timelines and regulatory plans.
• The planned resale registration and accredited-investor nature of the deal are important for liquidity and future trading of the shares; investors should monitor the registration filing and any subsequent disclosures for details.